Biotech Startups

Pairidex offers FusionMRD, a personalized digital droplet PCR (ddPCR) assay that detects and quantifies oncogenic gene fusions from a standard peripheral blood sample to monitor treatment response and minimal residual disease in gene fusion-driven blood cancers such as leukemia. It is sold as a commercial service for oncologists and clinical researchers to support treatment decisions and shorten clinical trial timelines.

2 investors

Pal, headquartered in Amsterdam, provides home-based care services for patients with serious illnesses. The company coordinates the support these patients and their families need so treatment and daily care can take place outside a hospital setting.

2 investors

Palobiofarma is a biopharmaceutical company that discovers and develops treatments for orphan diseases, including its PBF-999 candidate for Prader-Willi Syndrome. It is based in Pamplona, Spain.

2 investors

Palo Santo is a venture capital firm that invests in neuroscience and mental health companies, focusing on novel CNS therapeutics, next-generation psychedelic therapies, and brain health technologies. The firm targets solutions addressing the innovation gap in mental health treatment and psychiatric disorders.

2 investors

Pangea Biomed develops computational and data-driven platforms to advance precision oncology, helping researchers and clinicians select optimal cancer treatments and understand tumor biology. The company serves drug development teams, oncologists, and cancer centers globally.

2 investors

Pannex Therapeutics develops a novel drug class of proprietary Pannexin 1 (Panx1) channel blockers, targeting disease-relevant pathways shared across neurological disorders and cancer. Its initial programs focus on chronic neuropathic pain and triple-negative breast cancer, with plans to expand into broader neurology and oncology indications.

2 investors

Panome Bio provides metabolomics, proteomics, and multi-omics integration workflows along with a computational platform that analyzes and integrates diverse biological data types. It serves life science and biotechnology researchers looking to identify biomarkers and generate research insights.

2 investors

Provides open source tools, pretrained models, APIs, SDKs, and GPU-accelerated pipelines for healthcare and life sciences workloads including drug discovery, healthcare robotics, medical imaging, genomics, and digital health. The offering is built around NVIDIA AI infrastructure for developers and organizations in the healthcare and life sciences industry.

2 investors

Paradigm develops diagnostic tests for cancer, including assessments of hereditary risk, screening for the presence of cancer, and analysis of the genomic alterations in a patient's tumor to help guide treatment decisions. The company operates in the cancer diagnostics and genomics industry.

2 investors

Industry-leading private-equity backed CDMO focused on development and manufacturing of cutting-edge biopharmaceuticals

2 investors

Parallel Health offers a skincare product line addressing aging through microbiome science, including peptide creams and cleansers designed to target the hallmarks of skin aging.

2 investors

Paratek Pharma develops and commercializes specialty therapies for patients with life-threatening infectious diseases and difficult-to-treat conditions. The company's pipeline includes FDA-approved antibiotics and other pharmaceutical products targeting areas of unmet medical need.

2 investors

Pardes Biosciences develops oral medications designed to treat and prevent viral infections, including COVID-19.

2 investors

Parexel is a contract research organization (CRO) providing clinical development, regulatory consulting, and market access services for biopharmaceutical companies conducting clinical trials across phases I-IV globally. The company operates with a network of offices and specialized facilities across North America, Latin America, Europe, and Asia-Pacific.

2 investors

Parima is developing technology to reinvent how animal proteins are produced, working at the cellular level to make animal production more efficient and sustainable. It positions itself in the biotech and cellular/cultivated protein space.

2 investors

Patheon, part of Thermo Fisher Scientific, is a contract development and manufacturing organization (CDMO) that also offers clinical research (CRO) services for biotechnology and pharmaceutical sponsors. It supports drug development from early-stage R&D through clinical supply and commercial manufacturing across a global network of more than 60 sites.

2 investors

Path Fertility develops diagnostic tests for male reproductive health, using sperm epigenetics technology to identify subfertility that standard analysis misses. The tests enable earlier and more accurate diagnosis for couples pursuing fertility treatment.

2 investors

PathoQuest develops iDTECT, a platform of Next Generation Sequencing (NGS) assays for biopharmaceutical quality control, offering animal-free viral safety testing and genetic characterization of cell banks and biologics. The company was acquired by Charles River Labs to expand its end-to-end biologics testing portfolio.

2 investors

PathoScan provides portable, field-deployable pathogen detection technology for agronomists and growers, enabling rapid diagnosis of crop diseases within hours rather than days.

2 investors

Pattern develops rapid antibiotic susceptibility and infection diagnostics using single-cell microbiology, which reads the metabolic patterns of individual bacterial cells to deliver ID/AST results in hours without culture steps. Its phenotypic testing targets common infection sites to support faster, more focused antibiotic treatment in hospitals and combat antibiotic resistance.

2 investors

PDS Biotech develops T cell activating immunotherapies for cancer and infectious disease vaccines in clinical stages. The company operates proprietary platforms and maintains partnerships with major healthcare institutions including Merck, MD Anderson Cancer Center, National Cancer Institute, and Mayo Clinic.

2 investors

2 investors

Pensees develops cultivated meat produced by growing animal cells, using its patented 3D bioprinting technology. The company positions cultivated meat as a sustainable alternative for meat production.

2 investors

PEP-Therapy develops peptide-based therapeutic candidates for oncology, with a lead product in clinical trials targeting solid tumors including ovarian cancer and pancreatic cancer. The company uses an intracellular delivery technology platform to deliver peptides that restore apoptosis in cancer cells.

2 investors